Literature DB >> 15550136

Glaucoma induced by periorbital topical steroid use--a rare complication.

D Sahni1, C R Darley, J L M Hawk.   

Abstract

Eye complications arising during systemic and ophthalmic steroid use are well known. In contrast, there is little highlighting the similar risks associated with topical steroid use around the eyelids. We now describe a 29-year-old lady who used topical steroids in prolonged fashion throughout most of her life for severe eczema, with the recent application of large quantities of potent steroid continuously for one month, including to the periorbital region. Soon after, she presented to her ophthalmologist with severe bilateral glaucoma and irreversible visual loss attributed to the steroid use. Here we emphasise the possible risks of periorbital topical steroid use, as well as the importance of patient education and ophthalmological follow-up.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15550136     DOI: 10.1111/j.1365-2230.2004.01610.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  4 in total

1.  Ocular hypertensive response to topical dexamethasone ointment in children.

Authors:  Yoon Jung Lee; Chan Yi Park; Kyung In Woo
Journal:  Korean J Ophthalmol       Date:  2006-09

2.  Corticosteroids and open-angle glaucoma in the elderly: a population-based cohort study.

Authors:  Michael W Marcus; Rogier P H M Müskens; Wishal D Ramdas; Roger C W Wolfs; Paulus T V M De Jong; Johannes R Vingerling; Albert Hofman; Bruno H C Stricker; Nomdo M Jansonius
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

3.  Changes in Intraocular Pressure with Use of Periocular Triamcinolone Cream.

Authors:  Diana H Kim; Sana A Bautista; Elana Meer; Brendan McGeehan; Maureen G Maguire; César A Briceño
Journal:  J Ophthalmic Vis Res       Date:  2022-08-15

4.  Retrospective analysis of ocular adverse events with Clobetasol.

Authors:  Yu Wang; Joseph L Jorizzo
Journal:  Dermatol Ther       Date:  2022-05-29       Impact factor: 3.858

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.